NCT00363766 is a Phase 2 clinical trial of LY573636-sodium in Non-Small-Cell Lung Cancer, sponsored by Eli Lilly and Company.

Who is sponsoring NCT00363766?

NCT00363766 is sponsored by Eli Lilly and Company.

What drugs are being tested in NCT00363766?

Interventions in NCT00363766: LY573636-sodium.

What condition does NCT00363766 study?

NCT00363766 studies Non-Small-Cell Lung Cancer.

Is NCT00363766 still recruiting?

NCT00363766 is currently completed. Last updated 17 March 2018.

Are results published for NCT00363766?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-03-17 · How we verify

NCT00363766

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2 Study of LY573636-Sodium Administered as an Intravenous Infusion on Day 1 of a 21-Day Cycle as Third-line Treatment in Patients With Unresectable, Metastatic Non-Small Cell Lung Cancer

Completed Phase 2 Results posted Last updated 17 March 2018

What this trial tests

Phase 2 trial testing LY573636-sodium in Non-Small-Cell Lung Cancer in 52 participants. Completed in 1 October 2008.

Timeline

1 September 2006

Primary endpoint
1 October 2008

1 October 2008

Quick facts

Lead sponsor	Eli Lilly and Company
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	52
Start date	1 September 2006
Primary completion	1 October 2008
Estimated completion	1 October 2008
Sites	7 locations across Germany, Italy

Drugs / interventions tested

LY573636-sodium — full drug profile →

Conditions studied

Non-Small-Cell Lung Cancer — all drugs for Non-Small-Cell Lung Cancer →

Sponsor

Eli Lilly and Company — full company profile →

Who can join

18 and older, any sex, with Non-Small-Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Time to Progression
Time frame: First dose to measured progressive disease or death from study disease up to 10.35 months
Defined as the time from date of first dose to the first observation of progression of disease (PD) or death from study disease. PD was determined using the Response Evaluation Criteria In Solid Tumors (RECIST) criteria (version 1.0). PD is ≥20% increase in sum of longest diameter of target lesions and/or a new lesion.

Sponsor's own description

The primary objective is to estimate the time to progressive disease for patients who receive LY573636-sodium (hereafter referred to as LY573636) after two previous treatments for metastatic non-small cell lung cancer. Patients will receive an intravenous infusion of study drug once every 21 days. Computed tomography (CT)-scans will be done before the first dose and then after every other treatment.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling.
Parichatikanond W, Luangmonkong T, Mangmool S, Kurose H. · · 2020 · cited 118× · PMID 32211422 · DOI 10.3389/fcvm.2020.00034
RNA-binding protein 39: a promising therapeutic target for cancer.
Xu C, Chen X, Zhang X, Zhao D, et al · · 2021 · cited 57× · PMID 34389703 · DOI 10.1038/s41420-021-00598-7
Alternative splicing: from tumorigenesis to neoantigen-mediated cancer immunotherapy.
Lv YH, He YC, Dai XY, Yang XJ, et al · · 2025 · PMID 41316436 · DOI 10.1186/s40364-025-00877-w

Verify or expand the search:

Other recruiting trials for Non-Small-Cell Lung Cancer

Currently open trials in the same condition.

NCT07094204 — A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors · Phase 1 · recruiting
NCT06574347 — Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC. · Phase 2 · recruiting
NCT06476093 — SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer · NA · recruiting
NCT06015503 — A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metasta · Phase 2 · recruiting
NCT06343064 — Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI · Phase 1, PHASE2 · recruiting

Other Eli Lilly and Company trials

Trials by the same sponsor.

NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) · Phase 2 · not yet recruiting
NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo · Phase 2 · not yet recruiting
NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants · Phase 1 · completed
NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants · Phase 1 · completed
NCT07030127 — A Study of LY3985863 in Healthy Participants · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00363766 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
Last refreshed: 17 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00363766.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing